Clinical Trial: Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07204041) titled 'Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH' on Sept. 24.

Brief Summary: In adult patients with relapsed/refractory Langerhans cell histiocytosis (LCH), a treatment regimen of XTD regimen (Selinexor, Thalidomide and Dexamethasone) is planned to be used.

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Langerhans Cell Histiocytosis (LCH)

Intervention: DRUG: Selinexor

The combined treatment period includes 12 cycles: receiving Selinexor (60mg, D1, 8, 15, 22), Thalidomide (100mg, D1-28), and Dexamethasone (40mg, D1, 8, 15, 22) as oral ...